The trial is taking place at:
T

The Dermatology Center of Newport | Newport Beach, CA

Veeva-enabled site

Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome

Sol-Gel Technologies logo

Sol-Gel Technologies

Status and phase

Enrolling
Phase 3

Conditions

Gorlin Syndrome

Treatments

Drug: Patidegib Topical Gel with no active patidegib
Drug: Patidegib Topical Gel

Study type

Interventional

Funder types

Industry

Identifiers

NCT06050122
2023-507528-21-00 (Other Identifier)
SGT-610-01

Details and patient eligibility

About

The aim of this clinical study is to find out how well Patidegib Gel 2% works in preventing new basal cell carcinomas (BCCs) developing on the face of adults with Gorlin syndrome, and how safe Patidegib Gel 2% is to use. Participants will apply either Patidegib Gel 2% or a Vehicle Gel (with no active drug substance) to their face twice a day for a year (12 months). The number of new BCCs on the face will be compared between participants who used Patidegib Gel 2% or Vehicle Gel after 12 months.

Full description

This is a global, multicenter, randomized, double-blind, stratified, vehicle-controlled study of the efficacy and safety of Patidegib Gel 2%, applied topically twice daily to the face of adult participants with Gorlin syndrome. Participants will be randomized (1:1) to receive either Patidegib Gel 2% or Vehicle Gel for 12 months. The assignment of participants to the 2 groups will be stratified by sex assigned at birth, age (≥60 or <60 years), and number of facial BCC lesions (10-15, 16-30 or >30) at baseline. All BCCs at baseline, and any new BCCs which develop during the study, will be photographed and tracked during the study. New BCCs will be confirmed by dermoscopy analysis.

Enrollment

140 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

  • The subject must be at least 18 years old at the Screening Visit.
  • The subject must be confirmed to have a PTCH1 mutation.
  • The subject must have at least 10 BCCs on the face at Randomization (Baseline/Day 1).
  • The subject must be willing to abstain from application of any non-study topical medication (prescription or over the counter) to their facial skin for the duration of the trial, except as prescribed by the investigator.

Key Exclusion Criteria:

  • The subject has used topical treatment to the face or systemic therapies that might interfere with the evaluation of the study Investigational Product (IP).
  • The subject is known to have hypersensitivity to any of the ingredients in the IP formulation.
  • The subject has uncontrolled systemic disease.
  • The subject has been treated for invasive cancer within the past 5 years excluding chronic lymphocytic leukemia Stage 0 and non-melanoma skin cancer, Stage I cervical cancer, or ductal carcinoma in situ of the breast.
  • Previous Hedgehog inhibitor therapy was considered to have failed for reasons other than unfavorable side effect(s).

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

140 participants in 2 patient groups, including a placebo group

Patidegib Gel 2%
Experimental group
Description:
Patidegib Gel 2% (w/w), applied topically to the face twice daily for 12 months
Treatment:
Drug: Patidegib Topical Gel
Vehicle Gel
Placebo Comparator group
Description:
Vehicle Gel, applied topically to the face twice daily for 12 months
Treatment:
Drug: Patidegib Topical Gel with no active patidegib

Trial contacts and locations

8

Loading...

Central trial contact

Patient Referral Support Service

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems